{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:58:48Z","timestamp":1788829128602,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tranon.2026.102720","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:16:30Z","timestamp":1772154990000},"page":"102720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A2AR as a key target for immune microenvironment remodeling in prostate cancer"],"prefix":"10.1016","volume":"66","author":[{"given":"Lanzhi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tranon.2026.102720_bib0001","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/CIRCULATIONAHA.119.043319","article-title":"Increasing fatty acid oxidation prevents high-fat diet-induced cardiomyopathy through regulating parkin-mediated mitophagy","volume":"142","author":"Shao","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tranon.2026.102720_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"17-18","key":"10.1016\/j.tranon.2026.102720_bib0003","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.tranon.2026.102720_bib0004","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","article-title":"ACK1\/TNK2 Regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer","volume":"31","author":"Mahajan","year":"2017","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.tranon.2026.102720_bib0005","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-21-3603","article-title":"Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"649","key":"10.1016\/j.tranon.2026.102720_bib0006","doi-asserted-by":"crossref","first-page":"eabg4132","DOI":"10.1126\/scitranslmed.abg4132","article-title":"Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting","volume":"14","author":"Sawant","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102720_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101304","article-title":"Targeting the adenosine pathway for cancer immunotherapy","volume":"42","author":"Hammami","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.tranon.2026.102720_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113066","article-title":"CD39 - A bright target for cancer immunotherapy","volume":"151","author":"Guo","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2026.102720_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110543","article-title":"A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages","volume":"382","author":"Bai","year":"2023","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.tranon.2026.102720_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1165\/rcmb.2008-0168OC","article-title":"The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion","volume":"40","author":"Scheibner","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102720_bib0011","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.mucimm.2023.04.005","article-title":"A2Ar-dependent PD-1+ and TIGIT+ treg cells have distinct homing requirements to suppress autoimmune uveitis in mice","volume":"16","author":"Peters","year":"2023","journal-title":"Mucosal. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102720_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2026.102720_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570041","article-title":"Targeting hypoxia-A2A adenosinergic immunosuppression of antitumor T cells during cancer immunotherapy","volume":"11","author":"Steingold","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102720_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1100\/tsw.2011.22","article-title":"Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor","volume":"11","author":"Milne","year":"2011","journal-title":"Scie. World J."},{"issue":"17","key":"10.1016\/j.tranon.2026.102720_bib0016","article-title":"Biomimetic nanocarriers guide extracellular ATP homeostasis to remodel energy metabolism for activating innate and adaptive Immunity system","volume":"9","author":"Wu","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"4","key":"10.1016\/j.tranon.2026.102720_bib0017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the Immune System: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102720_bib0018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1873-3468.14270","article-title":"CAR-ts: new perspectives in cancer therapy","volume":"596","author":"Abrantes","year":"2022","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.102720_bib0020","first-page":"375","article-title":"Cancer immunotherapy, part 1: current strategies and agents","volume":"42","author":"Ventola","year":"2017","journal-title":"P. T."},{"issue":"9","key":"10.1016\/j.tranon.2026.102720_bib0021","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of Immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.tranon.2026.102720_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-021-01084-0","article-title":"Prostate cancer immunotherapy-finally in from the cold?","volume":"23","author":"Runcie","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"5","key":"10.1016\/j.tranon.2026.102720_bib0023","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030627","article-title":"Immunotherapy for prostate cancer","volume":"9","author":"Venturini","year":"2019","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.tranon.2026.102720_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122627","article-title":"Immunotherapy for prostate cancer: where we are headed","volume":"18","author":"Schepisi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.tranon.2026.102720_bib0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00345-020-03497-1","article-title":"Immunotherapy in prostate cancer: new horizon of hurdles and hopes","volume":"39","author":"Tsaur","year":"2021","journal-title":"World J. Urol."},{"issue":"24","key":"10.1016\/j.tranon.2026.102720_bib0026","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.tranon.2026.102720_bib0027","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1158\/0008-5472.CAN-20-0788","article-title":"Plasma gelsolin inhibits CD8 (+) T-cell function and regulates glutathione production to confer chemoresistance in ovarian cancer","volume":"80","author":"Asare-Werehene","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2026.102720_bib0029","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coph.2020.08.003","article-title":"Targeting the A2AR in cancer; early lessons from the clinic","volume":"53","author":"Willingham","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102720_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189005","article-title":"Adenosine in cancer immunotherapy: taking off on a new plane","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tranon.2026.102720_bib0031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.tranon.2026.102720_bib0032","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7150\/thno.51777","article-title":"Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics."},{"issue":"8","key":"10.1016\/j.tranon.2026.102720_bib0033","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0034","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0036","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","article-title":"Blockade of adenosine A2A receptor enhances CD8 (+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma","volume":"16","author":"Ma","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.102720_bib0038","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mam.2017.01.007","article-title":"Adenosine receptors: modulators of lipid availability that are controlled by lipid levels","volume":"55","author":"Leiva","year":"2017","journal-title":"Mol. Asp. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0039","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.102720_bib0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","article-title":"Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102720_bib0041","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.31557\/APJCP.2022.23.4.1239","article-title":"The prognostic role of CD73\/A2AR expression and tumor immune response in periampullary carcinoma subtypes","volume":"23","author":"Sweed","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tranon.2026.102720_bib0042","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102720_bib0043","article-title":"Current perspectives and trends of CD39-CD73-eAdo\/A2aR research in tumor microenvironment: a bibliometric analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102720_bib0044","first-page":"460","article-title":"Blocking Adenosine\/A2AR pathway for cancer therapy]","volume":"25","author":"Liu","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.tranon.2026.102720_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2020.07.005","article-title":"Oxygenation and A2AR blockade to eliminate hypoxia\/HIF-1alpha-adenosinergic immunosuppressive axis and improve cancer immunotherapy","volume":"53","author":"Halpin-Veszeleiova","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102720_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212209","article-title":"Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy","volume":"14","author":"Kurago","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102720_bib0047","article-title":"Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma","volume":"4","author":"Allard","year":"2023","journal-title":"Cell Rep. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:47:06Z","timestamp":1781509626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"alternative-id":["S1936523326000574"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102720","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A2AR as a key target for immune microenvironment remodeling in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102720"}}